drugset / Trial / NCT00490204

Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis

NCT00490204

Phase 3 Completed 239 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

Study objective is to verify the superiority of CTZ DS to the placebo groups in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period.

Timeline

Start
2007-07-27
Primary completion
2007-10-03
Completion
2007-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetirizine Other / unclassified 2.5 mg
Subject Cetirizine Other / unclassified 5 mg